CA3103707C - Composition normalisee d'extrait d'alcaloide psychoactif - Google Patents
Composition normalisee d'extrait d'alcaloide psychoactif Download PDFInfo
- Publication number
- CA3103707C CA3103707C CA3103707A CA3103707A CA3103707C CA 3103707 C CA3103707 C CA 3103707C CA 3103707 A CA3103707 A CA 3103707A CA 3103707 A CA3103707 A CA 3103707A CA 3103707 C CA3103707 C CA 3103707C
- Authority
- CA
- Canada
- Prior art keywords
- composition
- psychoactive
- alkaloid
- psychoactive alkaloid
- concentration
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Mycology (AREA)
- Alternative & Traditional Medicine (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Une composition dalcaloïde psychoactif comprend, en pourcentage massique, de 0,1 % à 99,9 % dun extrait dalcaloïde psychoactif et de 0,1 % à 99,9 % dun excipient. Lextrait psychoactif peut comprendre une concentration dalcaloïde psychoactif de 0,1 % à 99,0 %, selon les étapes dépuration. Les excipients comprennent un support, un agent fluidifiant et/ou un préservatif. La composition est normalisée à une quantité précise souhaitée dun alcaloïde psychoactif, qui peut être précisément définie et répétée de lot en lot. La composition peut être en forme de poudre à écoulement libre et est donc facile à manipuler pendant le procédé demballage ou de tabulation. La composition peut aussi comprendre dautres excipients.
Priority Applications (28)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA3103707A CA3103707C (fr) | 2020-12-18 | 2020-12-18 | Composition normalisee d'extrait d'alcaloide psychoactif |
IL299450A IL299450A (en) | 2020-06-17 | 2021-06-14 | Dephosphorylation-controlled extraction of phosphorylatable psychoactive alkaloids |
IL299448A IL299448A (en) | 2020-06-17 | 2021-06-14 | A process for obtaining a purified psychoactive alkaloid solution |
AU2021290454A AU2021290454B2 (en) | 2020-06-17 | 2021-06-14 | Process for Obtaining a Purified Psychoactive Alkaloid Solution |
IL299453A IL299453A (en) | 2020-06-17 | 2021-06-14 | Extraction and composition of psychoactive alkaloids with inhibited dephosphorylation |
IL298561A IL298561A (en) | 2020-06-17 | 2021-06-14 | Methanol-based extraction of psychoactive compounds from a mushroom |
IL299452A IL299452A (en) | 2020-06-17 | 2021-06-14 | Extraction and composition of psychoactive alkaloids with controlled dephosphorylation |
MX2022016533A MX2022016533A (es) | 2020-06-17 | 2021-06-14 | Composiciones que comprenden compuestos psicoactivos de organismos psicoactivos. |
IL299451A IL299451A (en) | 2020-06-17 | 2021-06-14 | Extraction of a psychoactive alkaloid is mainly by means of alkali |
EP21825817.6A EP4161546A1 (fr) | 2020-06-17 | 2021-06-14 | Compositions comprenant des composés psychoactifs à partir d'organismes psychoactifs |
CA3173030A CA3173030C (fr) | 2020-06-17 | 2021-06-14 | Extraction d'alcaloide psychoactif principalement phosphoryle au moyen d'alcali |
IL299449A IL299449A (en) | 2020-06-17 | 2021-06-14 | Standard psychoactive alkaloid extract composition |
IL305632A IL305632A (en) | 2020-06-17 | 2021-06-14 | Extraction of psychoactive compounds from psychedelic mushrooms |
PCT/CA2021/050813 WO2021253116A1 (fr) | 2020-06-17 | 2021-06-14 | Compositions comprenant des composés psychoactifs à partir d'organismes psychoactifs |
IL297791A IL297791A (en) | 2020-06-17 | 2021-06-14 | Compounds composed of psychoactive compounds from psychoactive organisms |
BR112022025780A BR112022025780A2 (pt) | 2020-06-17 | 2021-06-14 | Método para gerar um extrato de alcaloide psicoativo, método para gerar um extrato de alcaloide psicoativo fosforilado e método para gerar um extrato de alcaloide psicoativo desfosforilado |
US17/348,697 US11331357B2 (en) | 2020-06-17 | 2021-06-15 | Methods and compositions comprising psychoactive compounds from psychoactive organisms |
US17/351,149 US11382942B2 (en) | 2020-06-17 | 2021-06-17 | Extraction of psychoactive compounds from psilocybin fungus |
US17/483,601 US11298388B2 (en) | 2020-06-17 | 2021-09-23 | Psychoactive alkaloid extraction and composition with controlled dephosphorylation |
US17/587,731 US11510952B2 (en) | 2020-06-17 | 2022-01-28 | Ethanol extraction of psychoactive compounds from psilocybin fungus |
US17/697,798 US11571450B2 (en) | 2020-06-17 | 2022-03-17 | Aqueous extraction of psychoactive compounds from psilocybin fungus |
US17/702,701 US11642385B2 (en) | 2020-06-17 | 2022-03-23 | Basic extraction of psychoactive compounds from psychoactive organisms |
AU2022291411A AU2022291411B2 (en) | 2020-06-17 | 2022-12-19 | Psychoactive alkaloid extraction and composition with inhibited dephosphorylation |
AU2022291410A AU2022291410B2 (en) | 2020-06-17 | 2022-12-19 | Standardized psychoactive alkaloid extract composition |
AU2022291413A AU2022291413B2 (en) | 2020-06-17 | 2022-12-19 | Predominantly phosphorylated psychoactive alkaloid extraction using alkali |
AU2022291414A AU2022291414B2 (en) | 2020-06-17 | 2022-12-19 | Psychoactive alkaloid extraction and composition with controlled dephosphorylation |
AU2022291416A AU2022291416B2 (en) | 2020-06-17 | 2022-12-19 | Dephosphorylation-controlled extraction of phosphorylatable psychoactive alkaloids |
AU2023285751A AU2023285751A1 (en) | 2020-06-17 | 2023-12-19 | Powdered Composition Containing a Mushroom Extract Comprising a Psychoactive Alkaloid |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA3103707A CA3103707C (fr) | 2020-12-18 | 2020-12-18 | Composition normalisee d'extrait d'alcaloide psychoactif |
Publications (2)
Publication Number | Publication Date |
---|---|
CA3103707A1 CA3103707A1 (fr) | 2022-06-18 |
CA3103707C true CA3103707C (fr) | 2023-09-26 |
Family
ID=82016145
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA3103707A Active CA3103707C (fr) | 2020-06-17 | 2020-12-18 | Composition normalisee d'extrait d'alcaloide psychoactif |
Country Status (1)
Country | Link |
---|---|
CA (1) | CA3103707C (fr) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2023053090A1 (fr) * | 2021-10-01 | 2023-04-06 | Optimi Health Corp. | Technique d'extraction |
-
2020
- 2020-12-18 CA CA3103707A patent/CA3103707C/fr active Active
Also Published As
Publication number | Publication date |
---|---|
CA3103707A1 (fr) | 2022-06-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2021290454B2 (en) | Process for Obtaining a Purified Psychoactive Alkaloid Solution | |
CA3097246C (fr) | Processus d`obtention d`une solution alcaloide psychoactive purifiee | |
CA3123774C (fr) | Composition d'alcaloide psychoactif transdermique et preparation connexe | |
US11382942B2 (en) | Extraction of psychoactive compounds from psilocybin fungus | |
CA3173030C (fr) | Extraction d'alcaloide psychoactif principalement phosphoryle au moyen d'alcali | |
CA3103707C (fr) | Composition normalisee d'extrait d'alcaloide psychoactif | |
US11510952B2 (en) | Ethanol extraction of psychoactive compounds from psilocybin fungus | |
CA3137016C (fr) | Extraction d'alcaloide psychoactif et composition avec dephosphorylationattenuees | |
US11992476B2 (en) | Transdermal psychoactive alkaloid composition and preparation thereof | |
CA3169140A1 (fr) | Extraction d'alcaloides psychoactifs capables de phosphorylation a dephosphorylation controlee | |
EP4161549A1 (fr) | Procédé d'obtention d'une solution purifiée d'alcaloïde psychoactif |